National Health Act 1953 Amendment declaration under subsections 85(2) and 85(2AA) Amendment determination under subsection 85(2A) drugs and medicinal preparations (No. PB 50 of 2008) (Cth)

COMMONWEALTH OF AUSTRALIA

Instrument number PB 50 of 2008

Amendment declaration under subsections 85(2) and 85(2AA) of the National Health Act 1953

Amendment determination under subsection 85(2A) of the National Health Act 1953

I, DIANA MACDONELL, Acting Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsections 85(2), 85(2A) and 85(2AA) of the National Health Act 1953.

Dated    1st May                       2008

DIANA MACDONELL

Acting Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

Amendment declaration and determination — drugs and medicinal preparations

1              Commencement

This instrument commences on 1 June 2008.

2              Amendment of PB 88 of 2007

Schedule 1 amends PB 88 of 2007.

Schedule 1        Amendments

[1]       Schedule 1, after item dealing with Drotrecogin Alfa (activated)

insert in the columns in the order indicated:

Duloxetine Major depressive disorders

[2]       Schedule 1, item dealing with Flucloxacillin

omit from “Column 3”:

powder for oral suspension 125 mg (as magnesium) per 5 mL, 100 mL,

[3]       Schedule 1, item dealing with Glucose Indicator—Blood

insert in “Column 3” after “(TrueTrack),”:

electrode strips, 100 (FreeStyle Lite),

[4]       Schedule 1, after item dealing with Potassium Chloride with Potassium Bicarbonate

insert in the columns in the order indicated:

Pramipexole Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations

[5]       Schedule 1, item dealing with Tacrolimus

insert in “Column 3” as last paragraph:

Maintenance therapy of patients with lung transplants following initiation and stabilisation of treatment with tacrolimus, where therapy remains under the supervision and direction of the transplant unit reviewing that patient and where the name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit are included in the authority application

[6]       Schedule 2, item dealing with Flucloxacillin

omit from “Column 2”:

powder for oral suspension 125 mg (as magnesium) per 5 mL, 100 mL,